



UNITED STATES DEPARTMENT OF COMMERCE'
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

## NOTICE OF ALLOWANCE AND FEE(S) DUE

31048

7590

02/08/2002

ROBINS & PASTERNAK LLP 90 MIDDLEFIELD ROAD SUITE 200 MENLO PARK, CA 94025 EXAMINER

BECKERLEG, ANNE M

ART UNIT CLASS-SUBCLASS

1632 514-044000

DATE MAILED: 02/08/2002

1	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
	09/755,734	01/04/2001	Gregory M. Podsakoff	0800-0009.05	4811

TITLE OF INVENTION: METHODS FOR DELIVERING DNA TO THE BLOODSTREAM USING RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS

	TOTAL CLAIMS	APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
•	14	nonprovisional	YES	\$640	\$300	\$940	05/08/2002

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. <u>PROSECUTION ON THE MERITS IS CLOSED.</u> THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN <u>THREE MONTHS</u> FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. <u>THIS STATUTORY PERIOD CANNOT BE EXTENDED</u>. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE REFLECTS A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE APPLIED IN THIS APPLICATION. THE PTOL-85B (OR AN EQUIVALENT) MUST BE RETURNED WITHIN THIS PERIOD EVEN IF NO FEE IS DUE OR THE APPLICATION WILL BE REGARDED AS ABANDONED.

#### HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above. If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is changed, pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above and notify the United States Patent and Trademark Office of the change in status, or

B. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check the box below and enclose the PUBLICATION FEE and 1/2 the ISSUE FEE shown above.

 Applicant claims SMALL ENTITY status. See 37 CFR 1.27.

II. PART B - FEE(S) TRANSMITTAL should be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). Even if the fee(s) have already been paid, Part B - Fee(s) Transmittal should be completed and returned. If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Box ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.



#### PART B - FEE(S) TRANSMITTAL



#### Complete and mail this form, together with applicable fee(s), to:

**Box ISSUE FEE** Assistant Commissioner for Patents Washington, D.C. 20231

MAILING INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 4 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for

maintenance fee notifications. Note: The certificate of mailing below can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing. CURRENT CORRESPONDENCE ADDRESS (Note: Legibly mark-up with any corrections or use Block 1) 31048 02/08/2002 7590 **ROBINS & PASTERNAK LLP** Certificate of Mailing 90 MIDDLEFIELD ROAD I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an SUITE 200 MENLO PARK, CA 94025 envelope addressed to the Box Issue Fee address above on the date indicated below. (Depositor's name (Signature (Date APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 01/04/2001 0800-0009.05 09/755,734 Gregory M. Podsakoff TITLE OF INVENTION: METHODS FOR DELIVERING DNA TO THE BLOODSTREAM USING RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS TOTAL CLAIMS SMALL ENTITY ISSUE FEE **PUBLICATION FEE** TOTAL FEE(S) DUE APPLN. TYPE DATE DUE nonprovisional YES \$640 \$300 05/08/2002 **EXAMINER** ART UNIT **CLASS-SUBCLASS** BECKERLEG, ANNE M 1632 514-044000 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). Use of PTO form(s) and Customer Number are recommended, 2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered  $\mbox{\ensuremath{\square}}$  Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name ☐ "Fee Address" indication (or "Fee Address" Indication form is listed, no name will be printed. PTO/SB/47) attached. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) Please check the appropriate assignee category or categories (will not be printed on the patent) ☐ individual ☐ corporation or other private group entity ☐ government 4a. The following fee(s) are enclosed: 4b. Payment of Fee(s): ☐ A check in the amount of the fee(s) is enclosed. ☐ Issue Fee ☐ Payment by credit card. Form PTO-2038 is attached. ☐ Publication Fee ☐ The Commissioner is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number \_\_\_\_\_\_(enclose an extra copy of this form). ☐ Advance Order - # of Copies The COMMISSIONER OF PATENTS AND TRADEMARKS is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. (Authorized Signature) (Date) NOTE; The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office. Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, United States Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND FEES AND THIS FORM TO: Box Issue Fee,

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Assistant Commissioner for Patents, Washington, D.C. 20231





UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO	PPLICATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/755,734	09/755,734 01/04/2001		Gregory M. Podsakoff	0800-0009.05	4811	
31048	7590	02/08/2002		EXAMINER		
ROBINS & PASTERNAK LLP				BECKERLEG, ANNE M		
90 MIDDLEF SUITE 200	90 MIDDLEFIELD ROAD SUITE 200		,	ART UNIT	PAPER NUMBER	
MENLO PAR	K, CA 9402	25		1632		
			DATE MAILED: 02/08/2002			

# Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (application filed on or after May 29, 2000)

The patent term adjustment to date is 0 days. If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the term adjustment will be 0 days.

If a continued prosecution application (CPA) was filed in the above-identified application, the filing date that determines patent term adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) system. (http://pair.uspto.gov)

H12/C

	Application No.	Applicant(s)				
Notice of Allowability	09/755,734	PODSAKOFF ET AL.				
Notice of Allowability	Examiner	Art Unit				
	Anne M Beckerleg	1632				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.						
<ol> <li>This communication is responsive to applicant's amendment received on 11/27/01.</li> <li>The allowed claim(s) is/are 23-36.</li> <li>The drawings filed on 04 January 2001 are accepted by the Examiner.</li> <li>Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).         <ul> <li>All b)</li></ul></li></ol>						
6. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.  Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.  7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.						
<ul> <li>8.  CORRECTED DRAWINGS must be submitted.</li> <li>(a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached</li> <li>1) hereto or 2) to Paper No</li> <li>(b) including changes required by the proposed drawing correction filed, which has been approved by the Examiner.</li> <li>(c) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No</li> <li>Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the top margin (not the back) of each sheet. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftsperson.</li> </ul>						
9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.						
Attachment(s)						
1  Notice of References Cited (PTO-892) 3  Notice of Draftperson's Patent Drawing Review (PTO-948) 5  Information Disclosure Statements (PTO-1449), Paper No. 8 7  Examiner's Comment Regarding Requirement for Deposit of Biological Material	2 Notice of Informa 4 Interview Summa 6 Examiner's Ame 8 Examiner's State 9 Other	ary (PTO-413), Paper ndment/Comment	No. <u>11</u> .			

Art Unit: 1632

### **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Roberta Robbins on 1/30/02.

The application has been amended as follows:

- 1. In claims 28 and 34, line 1, the words "protein is secreted" have been replaced by the words -gene encodes a secreted protein --.
- 2. In claims 36, line 1, the words "AAV virions are" have been replaced by the words -pharmaceutical composition is --.

Any inquiry concerning this communication from the examiner should be directed to Anne Marie S. Beckerleg, Ph.D., whose telephone number is (703) 306-9156. The examiner can be reached Mon- Fri from 10:30-7:00. If the examiner is not available, the examiner's supervisor, Deborah Clark, can be reached at (703) 305-4051. General inquiries should be directed to the

Art Unit: 1632

group receptionist whose phone number is (703) 308-0196. The technology center fax number is (703) 308-4242, the examiner's direct fax number is (703) 746-7024.

Dr. A.M.S. Beckerleg

A.M.S. BECKERLEG PATENT EXAMINED